Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 54Leukemia, B-Cell 7Lymphoma, Mantle-Cell 5Leukemia 5Lymphoma 4Lymphoma, Non-Hodgkin 3Lymphoma, Large B-Cell, Diffuse 3Recurrence 2Leukemia, Prolymphocytic 2Hematologic Neoplasms 2Waldenstrom Macroglobulinemia 1Multiple Myeloma 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma, B-Cell 1Lymphatic Diseases 1Leukemia, Hairy Cell 1Hodgkin Disease 1Heart Failure 1Glioblastoma 1Chromosome 17 deletion 1Burkitt Lymphoma 1Anemia, Hemolytic, Autoimmune 1

Interventions

obinutuzumab 1acalabrutinib 1Standard of Care 1Rituximab 1Practice Guidelines as Topic 1Mesenchymal Stem Cell Transplantation 1Lenalidomide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Heart Failure × acalabrutinib × Other hematologic neoplasm × Clear all
NCT06651970 2026-05-18

Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure

AstraZeneca

Phase 4 Recruiting
60 enrolled
LymphoidOther hematologic neoplasm

Heart Failure, Lymphatic Diseases, Leukemia, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡